Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

(2017) A. De Gramont et al.   JOURNAL OF CLINICAL ONCOLOGY

Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66

(2010) Steven R. Alberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

(2009) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)

(2009) M. Ychou et al.   ANNALS OF ONCOLOGY

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

(2009) Sonja Loges et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

The nuances of therapy

(2009) Lee M. Ellis et al.   NATURE

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

(2009) Andrew R Reynolds et al.   NATURE MEDICINE

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

(2009) M. Kozloff et al.   ONCOLOGIST

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY